Scientific Advisory Council

The Connecting to Cure Crohn’s and Colitis (CtoC) Scientific Advisory Council recommends and advises the Board of Directors on research projects that will advance and accelerate our mission to find cures and treatments for Crohn’s Disease and ulcerative colitis. 

Marla C. Dubinsky, MD

Professor of Pediatrics

Chief, Pediatric Gastroenterology, Hepatology and Nutrition

Co-Director, Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center

Icahn School of Medicine, Mount Sinai Hospital New York, New York

Shervin Rabizadeh, MD, MBA 

Director of Pediatric Gastroenterology and Inflammatory Bowel Disease with the Cedars-Sinai Pediatrics Department. 

Dermot McGovern, MD, PhD, MRCP(UK)

Director, Translational Medicine, Inflammatory Bowel and Immunobiology Research Institute, Gastroenterology

Marla C. Dubinsky received a medical degree from Queen’s University in Canada and completed her clinical pediatric gastroenterology training at Sainte-Justine Hospital, University of Montreal in Quebec, Canada. Currently, Dr. Dubinsky is Chief of Pediatric Gastroenterology, Hepatology and Nutrition, Co-Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center and Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai Hospital Medical Center in New York. 


Board-certified in pediatrics and pediatric gastroenterology, Dr. Dubinsky holds positions of prominence with several advisory bodies, including Chair of the Western Regional Pediatric IBD Research Alliance and President of We Care in IBD. She is a member of several professional societies, including the American Gastroenterology Association, the American College of Gastroenterology, and the American Academy of Pediatrics. 


Dr. Dubinsky’s work has been published in numerous peer-reviewed journals, including Gastroenterology, The Journal of Pediatric Gastroenterology and Nutrition, Inflammatory Bowel Diseases, and the American Journal of Gastroenterology. In addition, she has authored book chapters for Trends in Inflammatory Bowel Disease Therapy and Inflammatory Bowel Disease: Diagnosis and Therapeutics. Dr. Dubinsky has lectured widely nationally and internationally. Dr. Dubinsky’s main research interests are the influence of genetics and immune responses on the variability in clinical presentations of early-onset IBD and prognosis.  Additional interests include the study of pharmacogenetics to evaluate how heredity influences drug responses and optimizing and individualizing the management of IBD as well as the impact of IBD on fertility and pregnancy.

Dr. Rabizadeh is a Diplomate of the American Academy of Pediatrics and a member of the American Gastrointestinal Association, North American Society of Pediatric Gastroenterology, Hepatology and Nutrition and American Academy of Pediatrics.

Dr. Rabizadeh has authored and co-authored numerous abstracts, book chapters and peer-reviewed articles in pediatrics, pediatric gastroenterology and inflammatory bowel disease (IBD). His clinical interests include autoimmune disorders of the gastrointestinal tract, IBD, celiac disease and eosinophilic gastreoenteritis. He is also active in laboratory research studying the relationship of bacteria, immunology, and inflammation as it pertains to diseases like IBD.

Dr. Rabizadeh received his bachelor's degree from the University of California, Los Angeles and his medical degree from Tufts University School of Medicine. He completed his pediatric residency, pediatric chief residency, and gastroenterology fellowship in the Department of Pediatrics at Johns Hopkins University School of Medicine.

Dermot McGovern, MD, Ph.D, FRCP(Lon), is the Director of Translational Medicine and Professor of Medicine at Cedars-Sinai Medical Center in Los Angeles. Dr. McGovern serves on the Steering Committee of the NIDDK IBD Genetics Consortium, the Management Committee of the International IBD Genetics Consortium, and the National Scientific Advisory Board of the Crohn's and Colitis Foundation of America (CCFA). Dr. McGovern completed his clinical training with a focus on Crohn's disease and ulcerative colitis in Oxford, UK and holds a doctorate from the University of Oxford on IBD Genetics. Dr. McGovern has been elected a Fellow of The Royal College of Physicians, London and The American Society of Clinical Investigation.


Dr. McGovern’s research group receive funding from the NIH, the European Union, The Leona M. and Harry B. Helmsley Charitable Trust, and the CCFA. The group's research has focused in identifying IBD susceptibility genes and also the functional consequences of these genes as well as the way genetic variation interacts with environmental factors including the microbiome. As an IBD clinician, Dr. McGovern is particularly interested in translating these basic science findings to the clinic through the development of models that predict disease behavior and response to therapy, as well as identifying new areas for the development of treatments for both Crohn's disease and ulcerative colitis. Dr. McGovern’s group has published numerous publications, in journals including Nature, Science, Nature Genetics, The American Journal of Human Genetics, The Lancet, GUT and Gastroenterology. Dr. McGovern has joined Stacy in raising money and awareness for IBD through 1/2 marathon and triathlons!

We Need Your Support Today!

Connecting to Cure Crohn's & Colitis Logo

Together we can build a community around our shared goal of supporting patients and funding research for these chronic diseases.


Registered Charity: 46-0767240

Together We'll Make A Difference

Get our monthly updates

© 2019 Connecting to Cure Crohn's and Colitis

Connecting to Cure Crohn's and Colitis, Inc. is a California nonprofit public benefit corporation that has received IRS recognition of federal tax-exempt status as a public charity under Section 501(c)(3) of the Internal Revenue Code (EIN #46-0767240).  Your contribution is tax-deductible to the extent allowed by law. Please consult your tax advisor for specific advice on the tax-deductibility of charitable contributions.